Bioverativ Inc. (BIVV)

104.3 +0.39 (+0.375%)

IEX Real-Time Price

February 23, 2018 EST.

Nasdaq Global Select : Healthcare

Prev Close 103.91

Price Open 104.6

Volume: 1.78M

Avg Volume: 3.32M

Market Cap: 11.29B

P/E Ratio 37.93

52 Wk Range 48.14-104.43



BIVV Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-01-31
107.95M
2.3M
0.67
2.13%

2018-01-12
107.95M
9.6M
8.79
8.89%

2017-12-29
107.93M
8.54M
7.28
7.91%

2017-12-15
107.93M
7.87M
4.95
7.29%




BIVV Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-02-13
Q4 2017
AMC
0.72 (2)
0.76
0.01

2018-01-25
Q4 2017
N/A
0.48 (2)
0.76
0.01

2017-10-26
Q3 2017
AMC
0.55 (2)
0.76
0.01

2017-08-02
Q2 2017
AMC
0.64 (2)
0.76
0.01

News

Sangamo Therapeutics: Great Start To 2018 - $3 Billion KITE Announcement (2018-02-22 12:14 SeekingAlpha)

Investment Thesis: Image captured from SGMO's ZFN presentation. Sangamo Therapeutics ( SGMO ) reported earnings on 2/22/18, beating the consensus for Q4 by $0.03 . They saw a significant increase in their revenues (+44.6% Y/Y) primarily due to revenues related to their strong partners…

 

Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A (2018-02-14 07:00 Business Wire)

Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders, today announced the publication of a retrospective analysis investigating the use of ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion …

 

Bioverativ beats by $0.06, beats on revenue (2018-02-13 16:20 SeekingAlpha)

Bioverativ (NASDAQ: BIVV ): Q4 EPS of $0.95 beats by $0.06 . More news on: Bioverativ Inc., Earnings news and commentary, Healthcare stocks news, Read more …

 

Bioverativ Reports Fourth Quarter and Full Year 2017 Performance (2018-02-13 16:15 Business Wire)

Full year 2017 year-over-year revenues up 31.7% Fourth quarter revenues up 28.3% year-over-year Full year 2017 GAAP operating margin of 38.3%; Non-GAAP operating margin of 46.5% Full year cash flows from operations of $591 million Bioverativ Inc. (NASDAQ: BIVV) today r…

 

The Law Offices of Vincent Wong Notifies Investors of an Investigation of Bioverativ Inc. in Connection with the Sale of the Company to Sanofi (2018-01-24 14:32 Business Wire)

The Law Offices of Vincent Wong are investigating the Board of Directors of Bioverativ Inc. (NASDAQGS: BIVV) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Sanofi. Under the terms of the deal, Bioverativ shareholders wi…

 

WeissLaw LLP Investigates Bioverativ Inc. Acquisition (2018-01-24 12:39 PR Newswire)

NEW YORK , Jan. 24, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Bioverativ Inc. ("BIVV" or the "Company") (NASDAQ: BIVV) in connection with the proposed acquisition of the Company by French…

 


Statistics

Shares Outstanding: 108.22M

Top 15 Institution Percent: 93.30

Price To Sales: 9.62

Price To Book: 12.53

Revenue: 1.17B

Gross Profit: 888.90M

Cash: 1.16B

Debt: N/A

Return On Assets: 28.99

Return On Equity: 46.08

Profit Margin: 29.86

Price History

Beta: 6.24

50-day Moving Avg: 78.12

200-day Moving Avg: 62.32

YTD Change: 89.81

5-day Change: 0.73

1-month Change: 0.49

3-month Change: 107.60

6-month Change: 85.13

1-year Change: 118.38

Revenue Per Share: 11.00

Revenue Per Employee: 3338571.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Bioverativ Inc.

Exchange: Nasdaq Global Select

Industry: Biotechnology

Sector: Healthcare

Website: http://www.bioverativ.com

Bioverativ Inc is a global biotechnology company which focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders.